Abbott Laboratories (NYSE:ABT) is set to face trial on Monday over allegations that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease known as necrotizing enterocolitis (NEC). This is the second trial out of hundreds of similar lawsuits in the U.S. Also Read: Class Action Against Abbott’s Glucerna Products Proceeds in Federal Court. Lawyers for Abbott and Illinois resident Margo Gill will make their opening statements to jurors in St. Louis, Missouri, with the trial expected to last most of the month. Gill claims her premature infant developed NEC after being fed Abbott’s products for premature babies, which causes the death of bowel tissue, primarily affects newborns, and has a fatality rate of 15% ...